Literature DB >> 15979951

Functional assessment of vascular reactivity after chronic intermittent hypoxia in the rat.

Blandine Lefebvre1, Diane Godin-Ribuot, Marie Joyeux-Faure, Françoise Caron, Germain Bessard, Patrick Lévy, Françoise Stanke-Labesque.   

Abstract

We recently developed a model of chronic intermittent hypoxia (CIH) (FiO2 5%, 8 h/day, 35 days) in the rat that was associated with an increased infarction in isolated heart. The aim of the present study was to characterize its functional consequences on vasoreactivity. Aorta and carotid artery were studied using organ bath technique while mesenteric vascular bed was perfused. In the three vascular beds, relaxation to acetylcholine was similar in CIH and control normoxic (NX) rats. Contractions to noradrenaline and angiotensin II were similar between CIH and NX rats. In contrast, contraction to endothelin-1 was increased by 17% (P < 0.05) in carotid artery from CIH rats. Indomethacin pre-treatment reduced by 24% (P < 0.001) contraction to endothelin-1 in carotid artery from CIH rats only. These data suggested that 35-day CIH-exposure induced no change in endothelial function of aorta, carotid artery and mesenteric bed. In contrast, CIH-exposure induced an increased contractile response to endothelin-1 in carotid artery, presumably owing to the release of constrictor cyclooxygenase-derived products.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15979951     DOI: 10.1016/j.resp.2005.05.020

Source DB:  PubMed          Journal:  Respir Physiol Neurobiol        ISSN: 1569-9048            Impact factor:   1.931


  15 in total

Review 1.  Targeting the ROS-HIF-1-endothelin axis as a therapeutic approach for the treatment of obstructive sleep apnea-related cardiovascular complications.

Authors:  Elise Belaidi; Jessica Morand; Emmanuelle Gras; Jean-Louis Pépin; Diane Godin-Ribuot
Journal:  Pharmacol Ther       Date:  2016-08-02       Impact factor: 12.310

Review 2.  Cardiovascular consequences of sleep apnea.

Authors:  Saeid Golbidi; Mohammad Badran; Najib Ayas; Ismail Laher
Journal:  Lung       Date:  2011-11-03       Impact factor: 2.584

3.  Development of a novel chronic intermittent hypoxia chamber.

Authors:  Chuangang Li; Jiming Lu; Bingxi Zhang
Journal:  Sleep Breath       Date:  2011-01-07       Impact factor: 2.816

4.  Chronic hypoxia alters fetal cerebrovascular responses to endothelin-1.

Authors:  Jinjutha Silpanisong; Dahlim Kim; James M Williams; Olayemi O Adeoye; Richard B Thorpe; William J Pearce
Journal:  Am J Physiol Cell Physiol       Date:  2017-05-31       Impact factor: 4.249

5.  NFATc3 is required for intermittent hypoxia-induced hypertension.

Authors:  Sergio de Frutos; Laura Duling; Dominique Alò; Tammy Berry; Olan Jackson-Weaver; Mary Walker; Nancy Kanagy; Laura González Bosc
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-03-21       Impact factor: 4.733

6.  Effect of NADPH oxidase inhibitor apocynin on the expression of hypoxia-induced factor-1α and endothelin-1 in rat carotid body exposed to chronic intermittent hypoxia.

Authors:  Xue Liu; Yan Deng; Jin Shang; Xiu-Hong Yang; Kui Liu; Hui-Guo Liu; Yong-Jian Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-04-17

Review 7.  Obstructive sleep apnea, immuno-inflammation, and atherosclerosis.

Authors:  Claire Arnaud; Maurice Dematteis; Jean-Louis Pepin; Jean-Philippe Baguet; Patrick Lévy
Journal:  Semin Immunopathol       Date:  2009-04-29       Impact factor: 9.623

Review 8.  Mechanisms of cardiovascular disease in obstructive sleep apnoea.

Authors:  Silke Ryan
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 9.  Vascular effects of intermittent hypoxia.

Authors:  Nancy L Kanagy
Journal:  ILAR J       Date:  2009

10.  Cerebral metabolic rate of oxygen in obstructive sleep apnea at rest and in response to breath-hold challenge.

Authors:  Zachary B Rodgers; Sarah E Leinwand; Brendan T Keenan; Lohith G Kini; Richard J Schwab; Felix W Wehrli
Journal:  J Cereb Blood Flow Metab       Date:  2015-09-30       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.